Get started
Author

Christopher J. Schaber

Observed names: C. Schaber, Christopher Schaber
ORCID: 0009-0000-4333-7111
Observed ORCID: 0009-0000-4333-7111
OpenAlex ID: A5111935910
A Multicenter, Randomized, Controlled Trial of Lucinactant Versus Poractant Alfa Among Very Premature Infants at High Risk for Respiratory Distress Syndrome
2005 · Sunil K. Sinha, Thierry Lacaze-Masmonteil, et al. · PEDIATRICS · 191
Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
2022 · Ellen J. Kim, Aaron R. Mangold, et al. · JAMA Dermatology · 56
A novel approach for emerging and antibiotic resistant infections: Innate defense regulators as an agnostic therapy
2016 · John R. North, Shunsuke Takenaka, et al. · Journal of Biotechnology · 30
PDF
Compatibility study of topical 0.25% hypericin (HyBryteTM) application in subjects with mycosis fungoides: Results of the HPN‐CTCL‐02 study
2024 · Carolina V. Alexander‐Savino, Adam Rumage, et al. · JEADV Clinical Practice · 3
Results from a pilot study of dusquetide for the treatment of aphthous ulcers associated with Behçet's syndrome
2025 · Oreola Donini, Bercemhan Sulu, et al. · Lara D. Veeken · 1
PDF
Results from a Pilot Study of HyBryte™ (Topical Synthetic Hypericin) Versus Valchlor® (Mechlorethamine) in the Treatment of CTCL
2026 · Brian Poligone, Christopher Pullion, et al. · Oncology and Therapy
PDF
A-182 Phase 2a Study of Topical 0.25% Hypericin in Mycosis Fungoides: Results and Review of the FLASH Study
2024 · B. Poligone, R. Straube, et al. · European Journal of Cancer
HyBryte™ use in early-stage cutaneous T-cell lymphoma
2023 · Brian Poligone, Carolina V. Alexander-Savino, et al. · Frontiers in Drug Discovery
Targeting innate immunity to treat disease: potential therapeutic applications
2018 · Oreola Donini, Richard Straube, et al.
Works count: 9
Citation count: 280
H-index: 3
I10-index: 3
Year
Topic
Type